Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Quality in Sport

Nasal Decongestants in Competitive Athletes: A Narrative Review
  • Home
  • /
  • Nasal Decongestants in Competitive Athletes: A Narrative Review
  1. Home /
  2. Archives /
  3. Vol. 75 (2026) /
  4. Medical Sciences

Nasal Decongestants in Competitive Athletes: A Narrative Review

Authors

  • Bartosz Minik Medical University of Lublin
  • Kamila Ryń Uniwersytet Medyczny w Lublinie https://orcid.org/0009-0003-4005-9584
  • Karolina Cieślewicz Medical University of Lublin
  • Kinga Szymańska-Zdyb https://orcid.org/0009-0007-5263-5947
  • Patrycja Nowaczek 1 Military Clinical Hospital with Outpatient Clinic: Lublin, Lublin, PL
  • Krzysztof Mirkowski University Clinical Hospital No. 1 in Lublin https://orcid.org/0009-0009-6976-0810
  • Barbara Braksal Medical University of Lublin
  • Zuzanna Wanda Szurek Medical University of Lublin
  • Zofia Chyła Medical University of Lublin https://orcid.org/0009-0006-0519-6163
  • Adam Miroński University Clinical Hospital No. 1 in Lublin https://orcid.org/0009-0006-1543-3126

DOI:

https://doi.org/10.12775/QS.2026.75.74958

Keywords

nasal obstruction, endurance athletes, competitive athletes, competitive sports, athletes, decongestants, nasal decongestants

Abstract

Background. Nasal obstruction is a common but often underestimated problem in endurance athletes, where breathing comfort, sleep quality, and recovery may affect training consistency and performance.

Aim. This narrative review summarizes current evidence on septal deviation, rhinitis, and chronic rhinosinusitis in endurance athletes, with emphasis on their possible impact on exercise performance.

Material and methods. PubMed and open-access sources were searched using terms related to nasal obstruction, septal deviation, rhinitis, chronic rhinosinusitis, athletes, endurance exercise, and performance. English-language full-text studies and reviews were prioritized. Athlete-specific sources were preferred, with selected clinical studies included when sports-related evidence was limited.

Results. Evidence indicates that nasal obstruction in athletes is usually multifactorial and most often linked to mucosal disease, especially rhinitis. Structural causes such as septal deviation may also be relevant. Direct evidence connecting nasal obstruction with reduced endurance performance is limited, but plausible mechanisms include increased upper airway resistance, impaired breathing comfort, altered breathing mode, poorer sleep, higher symptom burden, and reduced exercise tolerance. Symptoms may be particularly important in athletes exposed to chlorine by-products, cold dry air, seasonal allergens, and repeated high-volume ventilation.

Conclusions. Nasal obstruction should be considered a potentially modifiable factor in endurance athletes. Rhinitis is the best documented sinonasal disorder in this group, while chronic rhinosinusitis and septal deviation remain insufficiently studied. Further research is needed to determine whether treatment improves objective and subjective performance-related outcomes.

References

Baethge C, Goldbeck-Wood S, Mertens S. SANRA - a scale for the quality assessment of narrative review articles.

Res Integr Peer Rev. 2019;4:5. https://doi.org/10.1186/s41073-019-0064-8

Barroso O, Goudreault D, Carbó Banús M, Ayotte C, Mazzoni I, Boghosian T, Rabin O. Determination of urinary

concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing

medications to healthy subjects: implications for doping control analysis of these stimulants banned in sport.

Drug Test Anal. 2012;4(5):320-329. https://doi.org/10.1002/dta.291

Berry C, Wagner DR. Effect of pseudoephedrine on 800-m run times of female collegiate track athletes. Int J Sports

Physiol Perform. 2012;7(3):237-241. https://doi.org/10.1123/ijspp.7.3.237

Chester N, Reilly T, Mottram DR. Physiological, subjective and performance effects of pseudoephedrine and

phenylpropanolamine during endurance running exercise. Int J Sports Med. 2003;24(1):3-8.

https://doi.org/10.1055/s-2003-37195

Chester N, Mottram DR, Reilly T, Powell M. Elimination of ephedrines in urine following multiple dosing: the

consequences for athletes, in relation to doping control. Br J Clin Pharmacol. 2004;57(1):62-67.

https://doi.org/10.1046/j.1365-2125.2003.01948.x

Deckx L, De Sutter AIM, Guo L, Mir NA, van Driel ML. Nasal decongestants in monotherapy for the common cold.

Cochrane Database Syst Rev. 2016;10(10):CD009612. https://doi.org/10.1002/14651858.CD009612.pub2

Druce HM, Ramsey DL, Karnati S, Carr AN. Topical nasal decongestant oxymetazoline (0.05%) provides relief of

nasal symptoms for 12 hours. Rhinology. 2018;56(4):343-350. https://doi.org/10.4193/Rhin17.150

Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: a practice

parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. https://doi.org/10.1016/j.jaci.2020.07.007

Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold.

Am J Rhinol. 2008;22(5):491-496. https://doi.org/10.2500/ajr.2008.22.3202

Eccles R, Mårtensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in

patients with common cold. Curr Med Res Opin. 2010;26(4):889-899.

https://doi.org/10.1185/03007991003648015

European Medicines Agency. EMA confirms measures to minimise the risk of serious side effects with medicines

containing pseudoephedrine. Published January 26, 2024.

https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects-medicines-cont

aining-pseudoephedrine [Accessed July 2, 2026].

Fowler J, Chin CJ, Massoud E, Alrajhi Y. Rhinitis medicamentosa: a nationwide survey of Canadian

otolaryngologists. J Otolaryngol Head Neck Surg. 2019;48:70. https://doi.org/10.1186/s40463-019-0392-1

Gheorghiev MD, Hosseini F, Moran J, Cooper CE. Effects of pseudoephedrine on parameters affecting exercise

performance: a meta-analysis. Sports Med Open. 2018;4:44. https://doi.org/10.1186/s40798-018-0159-7

Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP. Muscular and cardiorespiratory effects of pseudoephedrine

in human athletes. Br J Clin Pharmacol. 2000;50(3):205-213. https://doi.org/10.1046/j.1365-2125.2000.00252.x

Gillies H, Derman WE, Noakes TD, Smith P, Evans A, Gabriels G. Pseudoephedrine is without ergogenic effects

during prolonged exercise. J Appl Physiol (1985). 1996;81(6):2611-2617.

https://doi.org/10.1152/jappl.1996.81.6.2611

Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997;52(Suppl 40):28-34.

https://doi.org/10.1111/j.1398-9995.1997.tb04883.x

Grimaldi-Bensouda L, Bégaud B, Rossignol M, Avouac B, Lert F, Rouillon F, et al. Decongestant use and the risk of

myocardial infarction and stroke: a case-crossover study. Sci Rep. 2021;11:4160.

https://doi.org/10.1038/s41598-021-83718-8

Hagen M, Varbiro G, Montanari E, Ballerini Fernandes M. Revisiting rhinitis medicamentosa: examining the

evidence on topical nasal decongestants. J Pharm Pract. 2026;39(2):117-139.

https://doi.org/10.1177/08971900251350510

Hallén H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than

placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy. 1997;27(5):552-558.

https://doi.org/10.1111/j.1365-2222.1997.tb00744.x

Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine:

systematic review and meta-analysis. Ann Pharmacother. 2007;41(3):381-390.

https://doi.org/10.1345/aph.1H679

Hodges K, Hancock S, Currell K, Hamilton B, Jeukendrup AE. Pseudoephedrine enhances performance in 1500-m

runners. Med Sci Sports Exerc. 2006;38(2):329-333. https://doi.org/10.1249/01.mss.0000183201.79330.9c

Hox V, Beyaert S, Bullens D, Couto M, Langer D, Hellings PW, et al. Tackling nasal symptoms in athletes: moving

towards personalized medicine. Allergy. 2021;76(9):2716-2729. https://doi.org/10.1111/all.14786

Jolley D, Dawson B, Maloney S, White J, Goodman C, Peeling P. Hydration and urinary pseudoephedrine levels

after a simulated team game. Int J Sport Nutr Exerc Metab. 2014;24(3):325-332.

https://doi.org/10.1123/ijsnem.2013-0076

Kasterka N, Kolasa M, Karbownik L, Figwer A, Figwer K, Dzitkowska K, et al. Exercise-induced laryngeal

obstruction in athletes with exertional dyspnoea: a narrative review of diagnostic challenges, management and

sport participation. Qual Sport. 2026;59:72749. https://doi.org/10.12775/QS.2026.59.72749

Matyja M, Kowalska M, Mazur A, Brodziak J, Fojcik K, Ciszewska W, et al. Rhinitis in swimmers: a clinical issue at

the intersection of sports medicine and otorhinolaryngology. Qual Sport. 2025;47:66927.

https://doi.org/10.12775/QS.2025.47.66927

McIntosh C, Clemm HH, Sewry N, Hrubos-Strøm H, Schwellnus MP. Diagnosis and management of nasal

obstruction in the athlete: a narrative review by subgroup B of the IOC Consensus Group on Acute Respiratory

Illness in the Athlete. J Sports Med Phys Fitness. 2021;61(8):1144-1158.

https://doi.org/10.23736/S0022-4707.21.12821-X

Medicines and Healthcare products Regulatory Agency. Nasal decongestant sprays and drops containing

xylometazoline hydrochloride/oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis

medicamentosa and tachyphylaxis with overuse. Drug Safety Update. Published April 30, 2026.

https://www.gov.uk/drug-safety-update/nasal-decongestant-sprays-and-drops-containing-xylometazoline-hydroc

hloride-slash-oxymetazoline-hydrochloride-increased-risk-of-rebound-congestion-rhinitis-medicamentosa-and-t

achyphylaxis-with-overuse [Accessed July 2, 2026].

Neighbors CL, Fernandez Salvador C, Zhu B, Camacho M, Tsai P. Intranasal corticosteroid and oxymetazoline for

chronic rhinitis: a systematic review. J Laryngol Otol. 2022;136(1):8-16.

https://doi.org/10.1017/S0022215121003364

Pietrucha T, Gołdyn M, Kubala K, Grabińska M, Halik P, Jusiak J. Subcutaneous versus sublingual allergen

immunotherapy in allergic rhinitis and asthma: a comparative narrative review. Qual Sport. 2026;51:68476.

https://doi.org/10.12775/QS.2026.51.68476

Pokrywka A, Kwiatkowska D, Gorczyca D. Problems of the use of pseudoephedrine by athletes. Int J Sports Med.

2009;30(8):569-572. https://doi.org/10.1055/s-0029-1202826

Price OJ, Walsted ES, Bonini M, Brannan JD, Bougault V, Carlsen KH, et al. Diagnosis and management of allergy

and respiratory disorders in sport: an EAACI task force position paper. Allergy. 2022;77(10):2909-2923.

https://doi.org/10.1111/all.15431

Pritchard-Peschek KR, Jenkins DG, Osborne MA, Slater GJ. Pseudoephedrine ingestion and cycling time-trial

performance. Int J Sport Nutr Exerc Metab. 2010;20(2):132-138. https://doi.org/10.1123/ijsnem.20.2.132

Pritchard-Peschek KR, Jenkins DG, Osborne MA, Slater GJ, Taaffe DR. The dose-response relationship between

pseudoephedrine ingestion and exercise performance. J Sci Med Sport. 2014;17(5):531-534.

https://doi.org/10.1016/j.jsams.2013.07.015

Roberts WO, Armstrong LE, Sawka MN, Yeargin SW, Heled Y, O'Connor FG. ACSM Expert Consensus Statement

on Exertional Heat Illness: Recognition, Management, and Return to Activity. Curr Sports Med Rep.

2023;22(4):134-149. https://doi.org/10.1249/JSR.0000000000001058

Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a

meta-analysis. Arch Intern Med. 2005;165(15):1686-1694. https://doi.org/10.1001/archinte.165.15.1686

Stinson RJ, Sadofsky LR. Part 1 - imidazolines and the changing face of nasal decongestants. Front Pharmacol.

2025a;16:1655252. https://doi.org/10.3389/fphar.2025.1655252

Stinson RJ, Sadofsky LR. Part II - imidazolines and rhinitis medicamentosa: how can we tackle the rebound

dilemma? Front Pharmacol. 2025b;16:1655254. https://doi.org/10.3389/fphar.2025.1655254

Surda P, Walker A, Putala M, Siarnik P. Prevalence of rhinitis in athletes: systematic review. Int J Otolaryngol.

2017;2017:8098426. https://doi.org/10.1155/2017/8098426

Thongngarm T, Assanasen P, Pradubpongsa P, Tantilipikorn P. The effectiveness of oxymetazoline plus intranasal

steroid in the treatment of chronic rhinitis: a randomized controlled trial. Asian Pac J Allergy Immunol.

2016;34(1):30-37.

Trinh KV, Kim J, Ritsma A, Kim K. Effect of pseudoephedrine in sport: a systematic review. BMJ Open Sport Exerc

Med. 2015;1(1):e000066. https://doi.org/10.1136/bmjsem-2015-000066

U.S. Food and Drug Administration. Proposed Administrative Order OTC000036: Amending Over-the-Counter

Monograph M012, Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for

Over-the-Counter Human Use. Published November 7, 2024.

https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=OrderDetail&orderid=OTC000036

[Accessed July 2, 2026].

Watanabe H, Foo TH, Djazaeri B, Duncombe P, Mackay IS, Durham SR. Oxymetazoline nasal spray three times

daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology.

2003;41(3):167-174.

World Anti-Doping Agency. TUE Physician Guidelines: Sinusitis/Rhinosinusitis. Version 2.0. November 2021a.

https://www.wada-ama.org/sites/default/files/resources/files/tue_physician_guidelines_sinusitis_rhinosinusitis_f

inal_november_2021.pdf [Accessed July 2, 2026].

World Anti-Doping Agency. World Anti-Doping Code. 2021b.

https://www.wada-ama.org/sites/default/files/resources/files/2021_wada_code.pdf [Accessed July 2, 2026].

World Anti-Doping Agency. International Standard: Prohibited List 2026. Effective January 1, 2026.

https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf [Accessed

July 2, 2026].

Yang X, Eremeeva K, Svistushkin V, Lisenkova D, Smolyarchuk E, Nedorubov A. Variants of rhinitis

medicamentosa treatment: a systematic review. Eur Arch Otorhinolaryngol. 2025;282:4407-4416.

https://doi.org/10.1007/s00405-025-09344-6

Zucker SM, Barton BM, McCoul ED. Management of rhinitis medicamentosa: a systematic review. Otolaryngol

Head Neck Surg. 2019;160(3):429-438. https://doi.org/10.1177/0194599818807891

Quality in Sport

Downloads

  • PDF

Published

2026-09-23

How to Cite

1.
MINIK, Bartosz, RYŃ, Kamila, CIEŚLEWICZ, Karolina, SZYMAŃSKA-ZDYB, Kinga, NOWACZEK, Patrycja, MIRKOWSKI, Krzysztof, BRAKSAL, Barbara, SZUREK, Zuzanna Wanda, CHYŁA, Zofia and MIROŃSKI, Adam. Nasal Decongestants in Competitive Athletes: A Narrative Review. Quality in Sport. Online. 23 September 2026. Vol. 75, p. 74958. [Accessed 25 September 2026]. DOI 10.12775/QS.2026.75.74958.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 75 (2026)

Section

Medical Sciences

License

Copyright (c) 2026 Bartosz Minik, Kamila Ryń, Karolina Cieślewicz, Kinga Szymańska-Zdyb, Patrycja Nowaczek, Krzysztof Mirkowski, Barbara Braksal, Zuzanna Wanda Szurek, Zofia Chyła, Adam Miroński

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Stats

Number of views and downloads: 19
Number of citations: 0

Search

Search

Browse

  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

nasal obstruction, endurance athletes, competitive athletes, competitive sports, athletes, decongestants, nasal decongestants
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop